Brian Hiestand to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Brian Hiestand has written about Randomized Controlled Trials as Topic.
Connection Strength
0.106
-
Hiestand B, Abraham WT. Implications of heart failure drug trials: COMET, CHARM, EPHESUS. Rev Cardiovasc Med. 2005; 6 Suppl 2:S4-11.
Score: 0.052
-
Riley RF, Miller CD, Russell GB, Harper EN, Hiestand BC, Hoekstra JW, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Mahler SA. Cost analysis of the History, ECG, Age, Risk factors, and initial Troponin (HEART) Pathway randomized control trial. Am J Emerg Med. 2017 Jan; 35(1):77-81.
Score: 0.029
-
Collins S, Storrow AB, Albert NM, Butler J, Ezekowitz J, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hiestand B, Hollander JE, Lanfear DE, Levy PD, Pang PS, Peacock WF, Sawyer DB, Teerlink JR, Lenihan DJ. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. J Card Fail. 2015 Jan; 21(1):27-43.
Score: 0.025